Article Text
Editorial
Pulmonary exacerbations as indicators of progression of lung disease in young children with CF
Statistics from Altmetric.com
Footnotes
-
Contributors Both authors were involved in drafting and reviewing the manuscript for important intellectual content.
-
Competing interests CHG receives funding from the US Cystic Fibrosis Foundation, the NIH (R01HL103965, R01 AI101307, P30 DK089507) and the FDA (R01 FD003704). CHG has participated on advisory board and received an unrestricted grant from Transave Inc; participated on an advisory board for KaloBios Pharm; and received an unrestricted grant from Vertex Pharmaceuticals to perform secondary data analyses. DBS has received funding from the US Cystic Fibrosis Foundation and the NIH.
-
Provenance and peer review Commissioned; internally peer reviewed.